

(51) International Patent Classification:
A61K 47/48 (2006.01)(21) International Application Number:
PCT/JP2015/002020(22) International Filing Date:
10 April 2015 (10.04.2015)


(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2014-081454 10 April 2014 (10.04.2014) JP(71) Applicant: **DAIICHI SANKYO COMPANY, LIMITED**
[JP/JP]; 3-5-1, Nihonbashi Honcho, Chuo-ku, Tokyo,
1038426 (JP).(72) Inventors: **HETTMANN, Thore**; c/o U3 Pharma GmbH,
Fraunhoferstr. 22, Martinsried, 82152 (DE). **ABRAHAM,**
Reimar; c/o U3 Pharma GmbH, Fraunhoferstr. 22, Martin-
sried, 82152 (DE). **BLUM, Sabine**; c/o U3 Pharma GmbH,
Fraunhoferstr. 22, Martinsried, 82152 (DE). **UENO, Sug-**
uru; c/o DAIICHI SANKYO COMPANY, LIMITED, 1-2-
58, Hiromachi, Shinagawa-ku, Tokyo, 1408710 (JP).(74) Agents: **OHNO, Seiji** et al.; OHNO & PARTNERS, Mar-
unouchi Kitaguchi Building 21F, 6-5, Marunouchi 1-
chome, Chiyoda-ku, Tokyo, 1000005 (JP).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).**Published:**

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: ANTI-HER3 ANTIBODY-DRUG CONJUGATE

(57) Abstract: To provide an antitumor drug
having excellent therapeutic effect, which is
excellent in terms of antitumor effect and
safety. Provided is an antibody-drug conjugate
in which an antitumor compound represented
by the following formula is conjugated to an
anti-HER3 antibody via a linker having a
structure represented by the formula: $-L^1-L^2-$
 $L^P-NH-(CH_2)n^1-L^3-(CH_2)n^2-C(=O)-$ or $-L^1-L^2-$
 L^P- (the anti-HER3 antibody is connected to
the terminal of L^1 , the antitumor compound is
connected to the carbonyl group of $-(CH_2)n^2-$
 $C(=O)-$ moiety or the C terminal of L^P , with
the nitrogen atom of the amino group at posi-
tion 1 as a connecting position).

From the INTERNATIONAL BUREAU

PCTNOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

To:

OHNO, Seiji
OHNO & PARTNERS, Marunouchi Kitaguchi
Building 21F, 6-5, Marunouchi 1-chome, Chiyoda-ku,
Tokyo
1000005
JAPON

Date of mailing (day/month/year) 14 April 2016 (14.04.2016)	
Applicant's or agent's file reference PD20-9009WO	IMPORTANT NOTIFICATION
International application No. PCT/JP2015/002020	International filing date (day/month/year) 10 April 2015 (10.04.2015)

1. The following indications appeared on record concerning:		
☒ the applicant	☐ the inventor	☐ the agent
☐ the common representative		
Name and Address U3 PHARMA GMBH Fraunhoferstr. 22, 82152 Martinstried, Germany	State of Nationality DE	State of Residence DE
	Telephone No.	
	Facsimile No.	
	E-mail address	
2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:		
☐ the person	☐ the name	☒ the address
☐ the nationality		
☐ the residence		
Name and Address U3 PHARMA GMBH Fraunhoferstr. 22, 82152 Martinsried, Germany	State of Nationality DE	State of Residence DE
	Telephone No.	
	Facsimile No.	
	E-mail address ☐ Notifications by e-mail authorized	
3. Further observations, if necessary:		
4. A copy of this notification has been sent to:		
☒ the receiving Office	☐ the International Preliminary Examining Authority	
☒ the International Searching Authority	☒ the designated Offices concerned	
☐ the Authority(ies) specified for supplementary search	☐ the elected Offices concerned	
	☐ other:	

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Kunz Akiko e-mail pt07.pct@wipo.int Telephone No. +41 22 338 74 07
Facsimile No. +41 22 338 90 90	

From the INTERNATIONAL BUREAU

PCTNOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

To:

OHNO, Seiji
OHNO & PARTNERS, Marunouchi Kitaguchi
Building 21F, 6-5, Marunouchi 1-chome, Chiyoda-ku,
Tokyo
1000005
JAPON

Date of mailing (day/month/year) 26 January 2016 (26.01.2016)	
Applicant's or agent's file reference PD20-9009WO	IMPORTANT NOTIFICATION
International application No. PCT/JP2015/002020	International filing date (day/month/year) 10 April 2015 (10.04.2015)

1. The following indications appeared on record concerning:		
☒ the applicant	☐ the inventor	☐ the agent
☐ the common representative		
Name and Address	State of Nationality	State of Residence
	Telephone No.	
	Facsimile No.	
	E-mail address	
2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:		
☒ the person	☐ the name	☐ the address
☐ the nationality		
☐ the residence		
Name and Address U3 PHARMA GMBH Fraunhoferstr. 22, 82152 Martinstried, Germany	State of Nationality DE	State of Residence DE
	Telephone No.	
	Facsimile No.	
	E-mail address ☐ Notifications by e-mail authorized	
3. Further observations, if necessary: The person identified in Box 2 has been added as applicant for all designated States.		
4. A copy of this notification has been sent to:		
☒ the receiving Office	☐ the International Preliminary Examining Authority	
☐ the International Searching Authority	☒ the designated Offices concerned	
☐ the Authority(ies) specified for supplementary search	☐ the elected Offices concerned	
	☐ other:	

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Asakura Yo e-mail pt07.pct@wipo.int Telephone No. +41 22 338 74 07
Facsimile No. +41 22 338 90 90	